Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CADET-BD trial of adjunctive candesartan for bipolar depression
ACTRN12620000703909Phase 3Recruiting
- Sponsor
- Deakin University
- Start
- Sep 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of candesartan in bipolar disorder (BD), sponsored by Deakin University. Primary endpoint: Change in severity of mood symptoms. Started Sep 2021; status: recruiting.
02
Drugs
candesartan
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on ACTRN12620000703909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000703909.